Skip to content

Resources

 

Hemophilia Treatment Centers

 

Many people with bleeding disorders use the resources of their hemophilia treatment center (HTC). Individuals who go to hemophilia treatment centers will not only find state-of-the art medical care, but also benefit from an experienced, caring staff that takes time to develop comprehensive treatment care plans for patients and families.

Local Hemophilia Treatment Centers:

 
  • Gulf States Hemophilia & Thrombophilia Center
    6655 Travis, Suite 100
    Houston, TX 77030
    Phone: 713-500-8360
  • Texas Children’s Hemophilia & Thrombosis Center
    6701 Fannin Street
    Suite 1580
    Houston, Texas 77030
    Phone: 832-822-4362
  • Children’s Blood and Cancer Center of Central Texas – Dell Children’s Specialty Pavillion
    4910 Mueller Blvd Ste 200
    Austin, TX 78723
    Phone: 512-628-1900
  • South Texas Hemophilia Treatment Center
    Gateway Medical Park
  • 8435 Wurzbach Road
    San Antonio, TX 78229
    Phone: 210-567-7000

Assistance Programs

Your Social Worker at your Hemophilia Treatment Center can help you navigate resources for financial assistance.

Please contact your Social Worker for a LSBDF Helping Hands referral application.

Hemophilia Assistance Program

Website-

Hemophilia Assistance Program

The Hemophilia Assistance Program helps Texans with hemophilia cover their medical bills. Assistance is provided with blood factor replacement products or reimbursement for health insurance premium payment.

Who is eligible for services?

HAP is available to anyone who

  • Lives in Texas
  • Is 18 or older
  • Has an income at or below 200 percent of federal poverty guidelines
  • Has a diagnosis of hemophilia from a licensed physician
  • Isn’t incarcerated or a ward of the state
  • Isn’t eligible for the Children with Special Health Care Needs Services Program, Medicaid or Medicare

PAN Foundation

https://www.panfoundation.org

News from HFA

  • Word from Washington: November 2022

    Midterm elections are mostly wrapped up as November draws to a close. The race between Sen. Raphael Warnock and Herschel Walker heads to a runoff in early December, but regardless of the outcome in that contest, control of the U.S. Senate remains – narrowly – with the Democrats. Control of the House of Representatives, by The post Word from Washington: November 2022 appeared first on Hemophilia Federation of America.

  • State of the States: Fall 2022

    In this edition of State of the States, South Dakota votes to expand Medicaid, Oregon receives landmark approval to provide continuous Medicaid coverage for young children, and Delaware joins 14 other states in protecting copay assistance for consumers. Midterm elections result in little change in partisan control of state legislatures while states race to prepare for the looming end of the COVID public health emergency and the prospect of mass Medicaid terminations. The post State of the States: Fall 2022 appeared first on Hemophilia Federation of America.

  • Press Release: First-Ever Gene Therapy Approved for Hemophilia B

    FOR IMMEDIATE RELEASE  First-Ever Gene Therapy Approved for Hemophilia B  National patient advocacy organization issues formal statement.  WASHINGTON, D.C., Nov. 23, 2022—Hemophilia Federation of America (HFA), a national advocacy leader for patients with bleeding disorders, released a statement considering recent news that the U.S. Federal Food and Drug Administration (FDA) approved CSL Behring’s (CSL) HEMGENIX® The post Press Release: First-Ever Gene Therapy Approved for Hemophilia B appeared first on Hemophilia Federation of America.

  • HFA Statement on FDA Approval of First-Ever Gene Therapy for Hemophilia B

    Five years ago, Hemophilia Federation of America articulated a broad vision that includes advocating for improved care and quality of life for those affected by bleeding disorders. Hemophilia imposes many burdens: painful and unpredictable bleeding; joint damage or other serious long-term complications; onerous treatment regimens; and numerous other constraints on personal and family life. HFA The post HFA Statement on FDA Approval of First-Ever Gene Therapy for Hemophilia B appeared first on Hemophilia Federation of America.

  • BioMarin Investigational Gene Therapy Updates

    An update for the hemophilia community from BioMarin regarding a previously reported serious adverse event in the ongoing hemophilia A gene therapy [valoctocogene roxaparvovec, BMN 270] Phase 3 study that was deemed, by the Independent Data Safety Monitoring Committee and the company, very unlikely to be related to the investigational therapy. Clinical Development Program Update The post BioMarin Investigational Gene Therapy Updates appeared first on Hemophilia Federation of America.